查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600931

人類微生物組市場：依疾病、技術、產品、治療領域、應用分類 - 全球預測 2025-2030

Human Microbiome Market by Disease (Acute Diarrhea, Autoimmune Disorders, Cancer), Technology (16s rRNA Sequencing, Cell Culture Technology, Computational Tools), Product, Therapeutic Area, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年人類微生物組市場價值為15.8億美元，預計到2024年將達到19.6億美元，複合年成長率為23.90%，到2030年將達到71.1億美元。

人體微生物組是指存在於人體表面和體內的龐大微生物群，包括細菌、病毒、真菌和其他微生物。這個定義延伸到影響消化、免疫力甚至心理健康的人類健康的重要因素。探索人類微生物組的需求有可能徹底改變健康治療和疾病預防。應用範圍從個人化醫療到益生菌，反映了醫療保健、製藥和生物技術行業的不同最終用途。根據市場洞察，不斷增加的研究投資和消費者對微生物相關健康益處的認知正在推動市場的強勁成長。影響成長的關鍵因素包括基因序列測定技術的進步以及生物技術公司和研究機構之間不斷加強的合作以開發創新治療方法。機會正在迅速出現，特別是在開發靶向益生菌和益生元、微生物組診斷以及發炎性腸道疾病腸道疾病和糖尿病等疾病的治療解決方案方面。為了利用這些優勢，公司應該專注於動態夥伴關係關係和持續的研究和開發，以推動微生物組產品融入主流應用。然而，成長受到高開發成本、監管挑戰以及理解微生物組動態的複雜性等限制因素的阻礙。關於基因組資料的隱私問題也是一個障礙。應對這些挑戰需要透明的監管途徑和協作，以加強資料準確性和隱私保護。創新和研究的最佳領域包括用於治療目的的綜合工程微生物組以及元基因組技術的進步，以便更好地了解宿主與微生物的相互作用。隨著公司努力利用微生物組資料來改善健康結果，市場正在迅速發展，並具有競爭和協作的特徵。因此，公司應採取結合紮實的研究、監管意識和市場多元化的策略方法，以實現這一前景廣闊的領域的業務成長。

主要市場統計
基準年[2023] 15.8億美元
預測年份 [2024] 19.6億美元
預測年份 [2030] 71.1億美元
複合年成長率（%） 23.90%

市場動態：揭示快速發展的人類微生物組市場的關鍵市場洞察

供需的動態交互作用正在改變人類微生物組市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 人們越來越關注人類微生物組治療的發展
    • 用於藥物發現、早期疾病檢測和診斷的人類微生物組
    • 益生菌和嬰兒營養中微生物組的需求不斷增加
  • 市場限制因素
    • 微生物組療法的專業知識有限且安全問題
  • 市場機會
    • 透過聯合研究和增加研究投資創造成長機會
    • 新型人類微生物組療法的開發
  • 市場挑戰
    • 基於人類微生物組的藥物中細菌種類數量和不確定性的理解的局限性

波特五力：駕馭人類微生物組市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對人類微生物組市場的外部影響

外部宏觀環境因素在塑造人類微生物組市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解人類微生物組市場的競爭格局

對人類微生物組市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人類微生物組市場供應商的績效評估

FPNV定位矩陣是評估人類微生物組市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 專注於開發人類微生物組療法
      • 用於藥物發現、早期疾病檢測和診斷的人類微生物組
      • 益生菌和嬰兒營養中微生物組的需求增加
    • 抑制因素
      • 缺乏微生物組治療的專業知識和安全問題
    • 機會
      • 擴大合作和研究投資以創造成長機會
      • 新治療藥物的開發
    • 任務
      • 了解細菌種類數量的限制以及基於人類微生物組的藥物的不確定性
  • 市場區隔分析
    • 技術：16s rRNA定序和體學技術的最新進展，用於研究人體分子因素和過程
    • 應用：人類微生物組在醫療保健診斷和治療中的應用越來越多，以解決各種健康狀況。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化
    • 智慧財產權情況

第6章人類微生物組市場：依疾病分類

  • 急性腹瀉
  • 自體免疫疾病
  • 癌症
  • 糖尿病
  • 精神障礙
  • 肥胖

第7章人類微生物組市場：依技術分類

  • 16s rRNA定序
  • 細胞培養技術
  • 計算工具
  • 高通量技術
  • 元基因組定序
  • 體學技術

第8章人類微生物組市場：依產品

  • 診斷設備
  • 藥物
  • 食品
  • 益生元和益生菌

第 9 章按治療領域分類的人類微生物組市場

  • 胃腸道疾病
  • 代謝紊亂
  • 皮膚病
  • 婦女健康

第10章人類微生物組市場：依應用分類

  • 診斷
  • 治療藥物

第11章美洲人類微生物組市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太人類微生物組市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲人類微生物組市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 臨床微生物組學宣布與 CosmosID 合併
    • 雀巢與 APC Microbiome 合作開發健康與福祉產品
    • 華盛頓大學醫學院建立新的微生物體研究中心

公司名單

  • Merck KGaA
  • Theriva Biologics, Inc.
  • BiomeSense, Inc.
  • Metabiomics Corporation
  • Exeliom Biosciences SAS
  • Ferring BV
  • Evelo Biosciences, Inc.
  • Locus Biosciences, Inc.
  • Intralytix, Inc.
  • Seres Therapeutics, Inc.
  • DuPont de Nemours, Inc.
  • Invivo Healthcare
  • Vedanta Biosciences, Inc.
  • Astarte Medical Partners, Inc
  • Synlogic, Inc.
  • Finch Therapeutics Group, Inc.
  • Rebiotix Inc.
  • Osel Inc.
  • Second Genome, Inc.
  • Enterome Bioscience
  • Axial Therapeutics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.
  • Azitra
  • Illumina, Inc.
  • BiomX Ltd.
  • AOBiome, LLC
Product Code: MRR-430D42AA0FCD

The Human Microbiome Market was valued at USD 1.58 billion in 2023, expected to reach USD 1.96 billion in 2024, and is projected to grow at a CAGR of 23.90%, to USD 7.11 billion by 2030.

The human microbiome refers to the vast consortium of microorganisms residing on and within the human body, encompassing bacteria, viruses, fungi, and other microbes. Its definition extends to a critical component of human health, influencing digestion, immunity, and even mental well-being. The necessity of exploring the human microbiome is driven by its potential to revolutionize health treatments and disease prevention. Applications span from personalized medicine to probiotics, reflecting diverse end-use arenas in healthcare, pharmaceuticals, and biotechnology industries. The market insights suggest robust growth fueled by increased research investment and consumer awareness of microbiome-related health benefits. Key influencing growth factors include technological advancements in genomic sequencing and growing collaborations between biotech firms and research institutions to develop innovative therapies. Opportunities are emerging rapidly, particularly in developing targeted probiotics and prebiotics, microbiome diagnostics, and therapeutic solutions for diseases like inflammatory bowel disease and diabetes. To capitalize on these, businesses should focus on dynamic partnerships and continuous R&D to drive microbiome-product integration into mainstream applications. However, limitations such as high development costs, regulatory challenges, and the complexity of understanding microbiome dynamics tempers growth. Privacy concerns regarding genomic data also pose barriers. Addressing these challenges requires transparent regulatory pathways and collaborations to enhance data accuracy and privacy protections. The best areas for innovation and research include synthetically engineered microbiomes for therapeutic purposes and advancing techniques in metagenomic analysis to better understand host-microbe interactions. The market is rapidly evolving, marked by a competitive yet collaborative nature as companies strive to harness microbiome data for improving health outcomes. Thus, firms should adopt a strategic approach combining robust research, regulatory awareness, and market diversification to achieve business growth in this promising domain.

KEY MARKET STATISTICS
Base Year [2023] USD 1.58 billion
Estimated Year [2024] USD 1.96 billion
Forecast Year [2030] USD 7.11 billion
CAGR (%) 23.90%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Microbiome Market

The Human Microbiome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased Focus on Development of Human Microbiome Therapy
    • Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
    • Increasing Demand for Microbiome in Probiotics and Infant Nutrition
  • Market Restraints
    • Limited Expertise and Safety Issue related to Microbiome Therapeutics
  • Market Opportunities
    • Increasing Collaborations and Research Investments to Create Growth Opportunities
    • Development of Novel Human Microbiome Therapeutic Products
  • Market Challenges
    • Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Human Microbiome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Microbiome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Microbiome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Microbiome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Microbiome Market

A detailed market share analysis in the Human Microbiome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Microbiome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Microbiome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include Merck KGaA, Theriva Biologics, Inc., BiomeSense, Inc., Metabiomics Corporation, Exeliom Biosciences SAS, Ferring B.V., Evelo Biosciences, Inc., Locus Biosciences, Inc., Intralytix, Inc., Seres Therapeutics, Inc., DuPont de Nemours, Inc., Invivo Healthcare, Vedanta Biosciences, Inc., Astarte Medical Partners, Inc, Synlogic, Inc., Finch Therapeutics Group, Inc., Rebiotix Inc., Osel Inc., Second Genome, Inc., Enterome Bioscience, Axial Therapeutics, Inc., Viome Life Sciences, Inc., Yakult Honsha Co., Ltd., Azitra, Illumina, Inc., BiomX Ltd., and AOBiome, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Microbiome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease, market is studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.
  • Based on Technology, market is studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.
  • Based on Product, market is studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.
  • Based on Therapeutic Area, market is studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health.
  • Based on Application, market is studied across Diagnostics and Therapeutics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
      • 5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
      • 5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
      • 5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
    • 5.2.2. Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Intellectual Property Landscape

6. Human Microbiome Market, by Disease

  • 6.1. Introduction
  • 6.2. Acute Diarrhea
  • 6.3. Autoimmune Disorders
  • 6.4. Cancer
  • 6.5. Diabetes
  • 6.6. Mental Disorders
  • 6.7. Obesity

7. Human Microbiome Market, by Technology

  • 7.1. Introduction
  • 7.2. 16s rRNA Sequencing
  • 7.3. Cell Culture Technology
  • 7.4. Computational Tools
  • 7.5. High-Throughput Technology
  • 7.6. Metagenomic Sequencing
  • 7.7. Omics Technology

8. Human Microbiome Market, by Product

  • 8.1. Introduction
  • 8.2. Diagnostic Devices
  • 8.3. Drugs
  • 8.4. Foods
  • 8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Gastrointestinal Disorders
  • 9.3. Metabolic Disorders
  • 9.4. Skin Disorders
  • 9.5. Women's Health

10. Human Microbiome Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
  • 10.3. Therapeutics

11. Americas Human Microbiome Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Human Microbiome Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Human Microbiome Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Microbiomics Announces Merger with CosmosID
    • 14.3.2. Nestle Partners APC Microbiome on Health and Wellbeing Products
    • 14.3.3. UW Medicine Launches a New Center to Study Microbiomes

Companies Mentioned

  • 1. Merck KGaA
  • 2. Theriva Biologics, Inc.
  • 3. BiomeSense, Inc.
  • 4. Metabiomics Corporation
  • 5. Exeliom Biosciences SAS
  • 6. Ferring B.V.
  • 7. Evelo Biosciences, Inc.
  • 8. Locus Biosciences, Inc.
  • 9. Intralytix, Inc.
  • 10. Seres Therapeutics, Inc.
  • 11. DuPont de Nemours, Inc.
  • 12. Invivo Healthcare
  • 13. Vedanta Biosciences, Inc.
  • 14. Astarte Medical Partners, Inc
  • 15. Synlogic, Inc.
  • 16. Finch Therapeutics Group, Inc.
  • 17. Rebiotix Inc.
  • 18. Osel Inc.
  • 19. Second Genome, Inc.
  • 20. Enterome Bioscience
  • 21. Axial Therapeutics, Inc.
  • 22. Viome Life Sciences, Inc.
  • 23. Yakult Honsha Co., Ltd.
  • 24. Azitra
  • 25. Illumina, Inc.
  • 26. BiomX Ltd.
  • 27. AOBiome, LLC

LIST OF FIGURES

  • FIGURE 1. HUMAN MICROBIOME MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN MICROBIOME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN MICROBIOME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN MICROBIOME MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ACUTE DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPUTATIONAL TOOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HIGH-THROUGHPUT TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METAGENOMIC SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY FOODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTIC & PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY WOMEN'S HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2023